Company news
Beyond Air, Inc. (NASDAQ:XAIR) news
Beyond Air, Inc. news releases on 6ix. Latest, Sep 2, 2026: Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
Press releases & updates
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
September 2, 2026
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
August 31, 2026
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
August 25, 2026
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
August 13, 2026
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
August 4, 2026
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
July 30, 2026
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
June 26, 2026
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
June 22, 2026
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
June 10, 2026
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
June 1, 2026
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
April 20, 2026
Beyond Air Expands Commercial Access for LungFit PH through a Purchasing Agreement with a Top 3 National Group Purchasing Organization
April 2, 2026
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
March 31, 2026
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
March 25, 2026
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
March 17, 2026
Beyond Air to Participate in the 38th Annual Roth Conference in March
March 11, 2026
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
March 9, 2026
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
February 20, 2026
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
February 13, 2026
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
February 4, 2026
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
January 27, 2026
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
January 26, 2026
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
January 14, 2026
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
December 30, 2025
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil
December 17, 2025
Beyond Air® Announces Transition of Chief Financial Officer
November 26, 2025
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
November 10, 2025
Beyond Air® Secures Up to $32 Million to Accelerate Growth
November 5, 2025
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast
October 23, 2025
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
September 22, 2025
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
September 8, 2025
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
August 20, 2025
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2025
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
July 25, 2025
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
July 22, 2025
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
June 17, 2025
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
June 16, 2025
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
May 20, 2025
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
April 24, 2025
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home
April 9, 2025
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site
March 31, 2025
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH
March 11, 2025
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 9, 2025
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
February 4, 2025
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast
January 26, 2025
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia
January 23, 2025
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
December 2, 2024
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
December 1, 2024
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2024